Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Clinical trial NCT06254066 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06254066
Sponsor: Zhejiang Cancer Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Female Breast Cancer Patients Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer HRD Positive Advanced Breast Cancer

Start date: 2024-04-16
Primary completion: 2026-09-30
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.